Carsgen Therapeutics Holdings
Carsgen Therapeutics Holdings, a pioneering biopharmaceutical company headquartered in China, focuses on the development of innovative cancer therapies. Founded in 2016, the company has rapidly established itself in the oncology sector, with a strong emphasis on CAR-T cell therapy and other advanced immunotherapies. With a commitment to transforming cancer treatment, Carsgen's core products include cutting-edge CAR-T therapies that target various malignancies, setting them apart through their unique mechanisms of action and patient-centric approach. The company has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. As a leader in the biopharmaceutical industry, Carsgen Therapeutics Holdings continues to drive advancements in cancer care, aiming to improve patient outcomes and redefine therapeutic possibilities.
DitchCarbon Score
How does Carsgen Therapeutics Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Carsgen Therapeutics Holdings's score of 10 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Carsgen Therapeutics Holdings's reported carbon emissions
In 2023, Carsgen Therapeutics Holdings reported total carbon emissions of approximately 15,327,770 kg CO2e, with Scope 1 emissions at about 3,639,120 kg CO2e and Scope 2 emissions at approximately 11,688,650 kg CO2e. This represents a decrease from 2022, where total emissions were about 17,179,520 kg CO2e, with Scope 1 at approximately 5,031,790 kg CO2e and Scope 2 at about 12,147,730 kg CO2e. In 2021, the company recorded total emissions of around 9,385,520 kg CO2e, with Scope 1 emissions of about 117,100 kg CO2e and Scope 2 emissions of approximately 9,268,410 kg CO2e. Despite these figures, Carsgen Therapeutics has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or SBTi (Science Based Targets initiative) commitments suggests that while the company is actively monitoring its emissions, it has yet to establish formalised strategies for significant reductions in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 117,100 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,268,410 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Carsgen Therapeutics Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
